×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Thyroid Disorder Market Trends

ID: MRFR/Pharma/2031-CR
118 Pages
Rahul Gotadki
July 2019

Thyroid Disorder Market Research Report Information by Type (Hypothyroidism and Hyperthyroidism), Treatment (Medications, Radioactive Iodine Therapy, and Surgery), Route of Administration (Oral, Intravenous and others), End-User (Hospitals, Clinics, and others) and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Thyroid Disorder Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Thyroid Disorder Market

The thyroid disorder market is witnessing significant trends driven by various factors such as increasing prevalence of thyroid disorders, advancements in diagnostic technologies, and evolving treatment approaches. Thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroid nodules, affect millions of individuals worldwide and require timely diagnosis and management to prevent complications. One notable trend in this market is the rising incidence of thyroid disorders, attributed to factors such as iodine deficiency, autoimmune diseases, genetic predisposition, and environmental factors. As awareness of thyroid health grows and diagnostic capabilities improve, more cases of thyroid disorders are being diagnosed and treated, driving market growth for thyroid disorder management products and services.

Technological advancements play a pivotal role in shaping market trends in the thyroid disorder market. Innovations in diagnostic imaging techniques such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) enable more accurate and detailed visualization of the thyroid gland and surrounding structures. Moreover, molecular diagnostic tests and biomarker assays facilitate the early detection of thyroid cancer and other thyroid-related conditions, improving patient outcomes and guiding treatment decisions. Additionally, telemedicine and remote monitoring technologies enable healthcare providers to remotely assess thyroid function, monitor medication adherence, and adjust treatment regimens as needed, enhancing patient convenience and access to care.

Furthermore, the COVID-19 pandemic has impacted market trends in the thyroid disorder market, influencing healthcare delivery, patient behavior, and treatment approaches. The pandemic has led to disruptions in routine medical care and delayed diagnosis and treatment of thyroid disorders due to resource constraints and safety concerns. However, telehealth services and virtual consultations have emerged as valuable tools for managing thyroid disorders remotely, enabling patients to consult with healthcare providers, refill prescriptions, and monitor their condition from the safety of their homes. Additionally, the pandemic has prompted greater emphasis on preventive healthcare and self-management strategies, driving demand for thyroid health monitoring devices and home-based testing kits.

Another significant trend in the thyroid disorder market is the increasing focus on personalized medicine and targeted therapies. Advances in genomic sequencing and molecular profiling enable healthcare providers to identify specific genetic mutations and molecular markers associated with thyroid cancer and other thyroid disorders. This knowledge allows for more precise diagnosis, prognosis, and treatment selection, optimizing therapeutic outcomes and minimizing side effects. Moreover, targeted therapies such as tyrosine kinase inhibitors and immunotherapy offer promising options for patients with advanced or refractory thyroid cancer, expanding the treatment armamentarium and improving survival rates.

Moreover, demographic shifts and changing lifestyle factors influence market trends in the thyroid disorder market. With aging populations and the increasing prevalence of obesity and autoimmune diseases, there is a growing burden of thyroid disorders worldwide. Additionally, environmental factors such as exposure to radiation, toxins, and pollutants contribute to thyroid dysfunction, further driving the demand for thyroid disorder management products and services. Furthermore, changing dietary patterns and lifestyle habits, including stress, lack of exercise, and poor nutrition, impact thyroid health and increase the risk of thyroid disorders, emphasizing the importance of preventive measures and early intervention.

Regulatory factors also play a significant role in shaping market trends in the thyroid disorder market. Regulatory agencies such as the FDA (Food and Drug Administration) and the European Medicines Agency (EMA) regulate the approval, manufacturing, and marketing of drugs, diagnostic tests, and medical devices used in the diagnosis and treatment of thyroid disorders. Compliance with regulatory standards and guidelines is essential for market entry and commercialization, ensuring product safety, efficacy, and quality. Additionally, reimbursement policies and insurance coverage for thyroid disorder management products and services vary across different regions and healthcare systems, influencing market access and pricing strategies for manufacturers and healthcare providers.

Author
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the projected market valuation of the Thyroid Disorder Market by 2035?

<p>The Thyroid Disorder Market is projected to reach a valuation of 3.948 USD Billion by 2035.</p>

What was the market valuation of the Thyroid Disorder Market in 2024?

<p>In 2024, the Thyroid Disorder Market was valued at 2.511 USD Billion.</p>

What is the expected CAGR for the Thyroid Disorder Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Thyroid Disorder Market during the forecast period 2025 - 2035 is 4.2%.</p>

Which companies are considered key players in the Thyroid Disorder Market?

<p>Key players in the Thyroid Disorder Market include AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, and Merck & Co.</p>

What are the projected revenues for Hypothyroidism and Hyperthyroidism segments by 2035?

<p>By 2035, the projected revenue for Hypothyroidism is 2.368 USD Billion, while Hyperthyroidism is expected to reach 1.58 USD Billion.</p>

What treatment options are available in the Thyroid Disorder Market and their projected revenues?

<p>Projected revenues for treatment options by 2035 include Medications at 1.949 USD Billion, Surgery at 1.174 USD Billion, and Radioactive iodine therapy at 0.825 USD Billion.</p>

How does the route of administration impact the Thyroid Disorder Market?

<p>By 2035, the Oral route of administration is projected to generate 1.951 USD Billion, indicating its significant role in the Thyroid Disorder Market.</p>

What are the expected revenues for different end-users in the Thyroid Disorder Market by 2035?

<p>By 2035, Hospitals are expected to generate 1.563 USD Billion, Clinics 1.174 USD Billion, and Others 1.211 USD Billion.</p>

How does the Thyroid Disorder Market's growth compare to other healthcare sectors?

<p>The Thyroid Disorder Market's growth, with a projected CAGR of 4.2%, suggests a steady expansion compared to other healthcare sectors.</p>

What factors may influence the growth of the Thyroid Disorder Market in the coming years?

<p>Factors such as advancements in treatment options and increasing awareness of thyroid disorders may influence the Thyroid Disorder Market's growth.</p>

Market Summary

As per Market Research Future analysis, the Thyroid Disorder Market Size was estimated at 2.511 USD Billion in 2024. The Thyroid Disorder industry is projected to grow from 2.617 USD Billion in 2025 to 3.948 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.2% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Thyroid Disorder Market is experiencing a dynamic shift towards personalized treatment and advanced diagnostic technologies.

  • North America remains the largest market for thyroid disorders, driven by increased awareness and screening initiatives. The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare expenditure and a growing patient population. Hypothyroidism continues to dominate the market as the largest segment, while hyperthyroidism is recognized as the fastest-growing segment. Key market drivers include the rising incidence of thyroid disorders and advancements in diagnostic technologies, which are shaping treatment approaches.

Market Size & Forecast

2024 Market Size 2.511 (USD Billion)
2035 Market Size 3.948 (USD Billion)
CAGR (2025 - 2035) 4.2%
Largest Regional Market Share in 2024 Americas

Major Players

<a href="https://www.abbvie.com/patients/products.html">AbbVie </a>(US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Merck &amp; Co. (US), Novartis (CH), <a href="https://www.pfizer.com/news/announcements/understanding-your-thyroid-key-energy-health">Pfizer </a>(US), Sanofi (FR), Takeda Pharmaceutical Company (JP), Amgen (US)

Market Trends

The Thyroid Disorder Market is currently experiencing notable transformations driven by various factors. An increasing prevalence of thyroid disorders, coupled with heightened awareness regarding the importance of early diagnosis and treatment, appears to be propelling market growth. Healthcare providers are increasingly focusing on innovative diagnostic tools and therapeutic options, which may enhance patient outcomes. Furthermore, the integration of advanced technologies in treatment protocols suggests a shift towards more personalized medicine, potentially improving the management of thyroid-related conditions. In addition, the rising demand for effective treatment options is likely to stimulate research and development activities within the pharmaceutical sector. This trend indicates a growing interest in novel therapies, including biologics and targeted treatments, which could redefine standard care practices. As the Thyroid Disorder Market evolves, stakeholders must remain vigilant to emerging trends and adapt strategies accordingly to meet the changing needs of patients and healthcare systems.

Increased Awareness and Screening

There is a growing recognition of thyroid disorders among the general population and healthcare professionals. This heightened awareness is leading to more frequent screenings and early diagnosis, which may contribute to improved patient outcomes.

Technological Advancements in Treatment

The Thyroid Disorder Market is witnessing a surge in the adoption of advanced technologies for treatment. Innovations such as minimally invasive surgical techniques and targeted therapies are becoming more prevalent, potentially enhancing the effectiveness of interventions.

Focus on Personalized Medicine

A shift towards personalized medicine is becoming evident in the management of thyroid disorders. Tailoring treatment plans to individual patient profiles may improve therapeutic efficacy and patient satisfaction, indicating a significant trend in the market.

Thyroid Disorder Market Market Drivers

Rising Healthcare Expenditure

The Thyroid Disorder Market is positively impacted by rising healthcare expenditure across various regions. As governments and private sectors allocate more funds towards healthcare, there is an increased focus on managing chronic conditions, including thyroid disorders. This trend is reflected in the growing availability of healthcare services, improved access to medications, and enhanced patient education initiatives. Higher healthcare spending is likely to facilitate better diagnosis and treatment options for patients suffering from thyroid disorders. Consequently, the Thyroid Disorder Market is expected to expand as more individuals seek care and treatment, driven by the availability of resources and support.

Growing Demand for Targeted Therapies

The Thyroid Disorder Market is witnessing a shift towards targeted therapies, which are designed to address specific molecular targets associated with thyroid disorders. This trend is driven by the increasing understanding of the underlying mechanisms of these conditions, leading to the development of more effective treatment options. Patients are increasingly seeking therapies that offer personalized approaches, which can lead to better management of their conditions. The market for targeted therapies is expected to grow as pharmaceutical companies invest in research and development to create innovative solutions. This focus on precision medicine not only enhances treatment efficacy but also aligns with the evolving expectations of patients within the Thyroid Disorder Market.

Rising Incidence of Thyroid Disorders

The Thyroid Disorder Market is experiencing growth due to the increasing prevalence of thyroid disorders, which affects millions worldwide. According to health statistics, conditions such as hypothyroidism and hyperthyroidism are becoming more common, particularly among women. This rise in incidence is attributed to various factors, including genetic predisposition and environmental influences. As awareness of these disorders grows, more individuals seek diagnosis and treatment, thereby driving demand for therapeutic options. The Thyroid Disorder Market is projected to expand as healthcare providers enhance screening practices and patients become more informed about their health. This trend suggests a potential increase in the market size, as more patients are likely to require ongoing management and treatment for their thyroid conditions.

Advancements in Diagnostic Technologies

The Thyroid Disorder Market is significantly influenced by advancements in diagnostic technologies. Innovations such as high-sensitivity thyroid function tests and imaging techniques have improved the accuracy of diagnosing thyroid disorders. These technologies enable healthcare professionals to detect conditions at earlier stages, which is crucial for effective treatment. The introduction of point-of-care testing devices has also facilitated quicker diagnosis, allowing for timely intervention. As diagnostic capabilities continue to evolve, the Thyroid Disorder Market is likely to see an increase in patient referrals and treatment initiation, ultimately contributing to market growth. Enhanced diagnostic tools not only improve patient outcomes but also expand the overall market by attracting more patients seeking reliable testing.

Increased Investment in Research and Development

The Thyroid Disorder Market is benefiting from increased investment in research and development (R&D) aimed at understanding thyroid disorders better and developing new treatment modalities. Pharmaceutical companies and research institutions are allocating significant resources to explore novel therapeutic agents and improve existing treatments. This influx of funding is likely to accelerate the pace of innovation within the Thyroid Disorder Market, leading to the introduction of new drugs and therapies that can address unmet medical needs. As R&D efforts continue to expand, the market is expected to evolve, offering patients more options and potentially improving overall health outcomes.

Market Segment Insights

By Thyroid Disorder Type Outlook: Hypothyroidism (Largest) vs. Hyperthyroidism (Fastest-Growing)

<p>The Thyroid Disorder Market exhibits a distinct segmentation wherein hypothyroidism dominates, attributed to its higher prevalence and awareness among patients and healthcare providers. This segment accounts for a substantial portion of the market, significantly influenced by the aging population and rising incidence rates of thyroid-related diseases. In contrast, hyperthyroidism is gaining traction, gradually increasing its market share as awareness, diagnostic practices, and treatment options for this condition improve. Growth trends within the Thyroid Disorder Market indicate that while hypothyroidism remains the largest segment, hyperthyroidism is emerging as the fastest-growing area. The increasing focus on early diagnosis and treatment, coupled with advancements in pharmaceuticals, contributes to hyperthyroidism's rapid growth. Moreover, the prevalence of risk factors such as autoimmune disorders and stress in modern lifestyles acts as a significant driver for this transformation, making hyperthyroidism a focal point for future market strategies.</p>

<p>Hypothyroidism: Dominant vs. Hyperthyroidism: Emerging</p>

<p>Hypothyroidism is characterized by an underactive thyroid gland, leading to insufficient hormone production responsible for regulating metabolism. This segment has established itself as the dominant player within the Thyroid Disorder Market, greatly influenced by the high prevalence rates and ongoing education initiatives urging individuals to seek medical advice. Patients are often treated with hormone replacement therapies, which ensure consistent demand. On the other hand, hyperthyroidism presents as an emerging segment, marked by an overactive thyroid that accelerates metabolism. Current trends suggest that hyperthyroidism is on an upward trajectory, propelled by advancements in diagnostic tools and treatments. This emerging position attracts significant interest from pharmaceutical companies seeking to develop innovative therapies that cater to the growing patient population.</p>

By Thyroid Disorder Treatment Outlook: Medications (Largest) vs. Surgery (Fastest-Growing)

<p>The Thyroid Disorder Treatment Market shows a diverse distribution of treatment options, with medications holding the largest market share. This segment is favored for its non-invasive approach and effectiveness in managing hormone levels, making it a preferred choice among patients. In contrast, surgery, though accounting for a smaller percentage, is rapidly gaining traction as an effective option for certain types of thyroid disorders, prompting significant interest from healthcare professionals. Recent trends indicate a growing awareness of thyroid disorders, leading to increased diagnosis and treatment rates. Medications are often first-line treatments, but surgical options are becoming increasingly popular due to advancements in techniques and technologies. As patients seek comprehensive solutions, the market is evolving, resulting in a surge in surgical interventions that cater to more severe cases, thereby driving growth in this segment.</p>

<p>Medications (Dominant) vs. Surgery (Emerging)</p>

<p>Medications stand out as the dominant force within the Thyroid Disorder Treatment segment, primarily due to their effectiveness in controlling hormone levels and managing symptoms associated with hypothyroidism and hyperthyroidism. With a wide range of options that include levothyroxine and antithyroid medications, this segment appeals to patients looking for less invasive treatment. On the other hand, surgery is the emerging choice for patients suffering from nodular thyroid disease or cancer, where medications may not be sufficient. This trend is powered by advancements in surgical techniques, such as minimally invasive procedures, which have significantly reduced recovery times and risks. Thus, while medications will maintain dominance, surgery is poised for growth as clinical practices evolve.</p>

By Thyroid Disorder Route of Administration Outlook: Oral (Largest) vs. Intravenous (Fastest-Growing)

<p>In the Thyroid Disorder Market, the distribution of routes of administration has shown distinct preferences, with the oral segment commanding the largest share. This preference is largely reflective of its convenience, ease of consumption, and established efficacy among patients. Consequently, the oral route remains the predominant choice for managing thyroid conditions, significantly influencing market dynamics and product development.</p>

<p>Oral (Dominant) vs. Intravenous (Emerging)</p>

<p>The oral administration route for thyroid disorder treatments has established itself as the dominant segment due to its patient-friendly nature. Medications administered orally offer convenient dosage forms like tablets and capsules, making adherence easier for patients. In contrast, intravenous administration is emerging rapidly, primarily driven by the need for faster therapeutic effects and improved bioavailability in certain patient populations. While oral medications remain the favored choice for long-term management, intravenous treatments are gaining traction for acute care scenarios, signifying a shift towards more personalized treatment options in the thyroid disorder market.</p>

By Thyroid Disorder End-User Outlook: Clinics (Largest) vs. Hospitals (Fastest-Growing)

<p>The Thyroid Disorder Market has seen notable segmentation based on end-user outlook, dominated primarily by clinics. Clinics account for a significant portion of the market share, attributed to their accessibility and the convenience they offer for patients seeking diagnosis and treatment. Hospitals follow as a substantial component, benefiting from their comprehensive care capabilities, but are not as prevalent as clinics in day-to-day outpatient management.</p>

<p>Clinics (Dominant) vs. Hospitals (Emerging)</p>

<p>Clinics are the dominant force in the Thyroid Disorder Market due to their focus on outpatient services and specialized care tailored for thyroid conditions. These establishments often provide personalized treatment plans and follow-ups, fostering strong patient relationships. In contrast, hospitals, while currently emerging as a growing segment, are increasingly focusing on expanding their outpatient services for thyroid disorders. They boast advanced medical technologies and specialist networks, allowing them to attract more patients seeking comprehensive care, thus marking a significant pivot in the thyroid disorder care landscape.</p>

Get more detailed insights about Thyroid Disorder Market Research Report - Forecast till 2035

Regional Insights

North America : Leading Market for Innovation

North America is the largest market for thyroid disorders, accounting for approximately 45% of the global market share. The region's growth is driven by increasing prevalence of thyroid diseases, heightened awareness, and advancements in treatment options. Regulatory support from agencies like the FDA facilitates faster drug approvals, enhancing market dynamics. The demand for innovative therapies and personalized medicine is also on the rise, further propelling market growth. The United States is the leading country in this region, with significant contributions from Canada. Major pharmaceutical companies such as AbbVie, Eli Lilly, and Merck & Co. are actively involved in developing and marketing thyroid disorder treatments. The competitive landscape is characterized by a focus on research and development, with companies investing heavily in new therapies to meet the growing demand for effective treatment options.

Europe : Emerging Market with Growth Potential

Europe is witnessing significant growth in the thyroid disorder market, holding approximately 30% of the global share. The increasing incidence of thyroid-related conditions, coupled with rising healthcare expenditure, is driving demand for effective treatments. Regulatory frameworks in countries like Germany and France are supportive of innovative therapies, which enhances market accessibility and patient care. The region is also focusing on preventive healthcare measures, which is expected to further boost market growth. Leading countries in Europe include Germany, France, and the UK, where key players like Novartis and Sanofi are making substantial investments. The competitive landscape is marked by collaborations and partnerships aimed at enhancing product offerings. The presence of well-established healthcare systems facilitates the introduction of new therapies, ensuring that patients have access to the latest treatment options available.

Asia-Pacific : Rapidly Growing Healthcare Sector

The Asia-Pacific region is emerging as a significant player in the thyroid disorder market, accounting for about 20% of the global market share. The growth is driven by increasing awareness of thyroid health, rising disposable incomes, and improvements in healthcare infrastructure. Countries like China and India are witnessing a surge in demand for thyroid treatments, supported by government initiatives aimed at enhancing healthcare access and affordability. Regulatory bodies are also streamlining approval processes for new therapies, fostering market growth. China is the largest market in this region, followed by India, where local and international players are competing to capture market share. Companies like Takeda and Amgen are actively involved in the development of innovative therapies. The competitive landscape is characterized by a mix of multinational corporations and local firms, all striving to meet the growing demand for effective thyroid disorder treatments. This dynamic environment is expected to drive further advancements in the sector.

Middle East and Africa : Untapped Market with Potential

The Middle East and Africa region is gradually emerging in the thyroid disorder market, holding approximately 5% of the global share. The growth is primarily driven by increasing awareness of thyroid health issues and the rising prevalence of thyroid disorders. Government initiatives aimed at improving healthcare access and affordability are also contributing to market expansion. Regulatory bodies are working to enhance the approval processes for new treatments, which is expected to stimulate market growth in the coming years. Leading countries in this region include South Africa and the UAE, where there is a growing presence of international pharmaceutical companies. The competitive landscape is evolving, with both local and The Thyroid Disorder. Companies are focusing on partnerships and collaborations to enhance their product offerings and meet the increasing demand for effective thyroid disorder treatments.

Key Players and Competitive Insights

The Thyroid Disorder Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing awareness of thyroid-related health issues. Key players such as AbbVie (US), Eli Lilly and Company (US), and Novartis (CH) are strategically positioned to leverage innovation and expand their market presence. AbbVie (US) focuses on developing novel therapies, while Eli Lilly and Company (US) emphasizes partnerships to enhance its product portfolio. Novartis (CH) is actively pursuing regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is increasingly focused on patient-centric solutions and advanced therapeutic options.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Thyroid Disorder Market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, yet the collective strategies of these companies indicate a trend towards consolidation and collaboration, particularly in research and development initiatives.

In August 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of thyroid hormone replacement therapies. This collaboration is expected to accelerate the development timeline and enhance the therapeutic efficacy of treatments, thereby positioning AbbVie (US) as a frontrunner in the market. The strategic importance of this partnership lies in its potential to address unmet medical needs and improve patient outcomes, which is increasingly becoming a focal point in the industry.

In September 2025, Eli Lilly and Company (US) launched a digital health platform aimed at improving patient engagement and adherence to thyroid disorder treatments. This initiative reflects a broader trend towards digitalization in healthcare, where technology is utilized to enhance patient experiences and outcomes. The strategic significance of this move is profound, as it not only strengthens Eli Lilly's (US) market position but also aligns with the growing demand for integrated healthcare solutions that prioritize patient-centric care.

In July 2025, Novartis (CH) expanded its manufacturing capabilities in Asia to meet the rising demand for thyroid medications in the region. This expansion is indicative of Novartis's (CH) commitment to regional growth and its strategy to ensure supply chain reliability. The implications of this move are substantial, as it positions Novartis (CH) to better serve a burgeoning market while also mitigating potential supply chain disruptions that could arise from global uncertainties.

As of October 2025, current competitive trends in the Thyroid Disorder Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are shaping the landscape, fostering innovation and enhancing the development of advanced therapies. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and the reliability of supply chains, thereby ensuring that companies remain agile and responsive to the ever-changing healthcare environment.

Key Companies in the Thyroid Disorder Market include

Industry Developments

Recent development in the thyroid disorder market are

• In November 2015, a program that focuses on managing the daily routine of those having the life-long condition of hypothyroidism was launched by Abbie under Good Morning Hypothyroidism (GMH).

• In October 2016, ThyroTest was introduced by Abbott acquired Alere Inc., a service provider organization and a diagnostic device manufacturer introduced in the market, which is a test to detect hypothyroidism.

• In March 2018, an orally available tyrosine kinase inhibitor was discovered by Eisai.

• Also, in the same month, it was announced by Eisai Co Ltd and Merck about their strategic collar radiation. They are popularly called MSD after the collaboration.

• The commercialization of LENVIMA was also done in the year 2018.

Future Outlook

Thyroid Disorder Market Future Outlook

The Thyroid Disorder Market is projected to grow at a 4.2% CAGR from 2024 to 2035, driven by increasing prevalence, advancements in diagnostics, and enhanced treatment options.

New opportunities lie in:

  • Development of telehealth platforms for remote patient monitoring
  • Investment in AI-driven diagnostic tools for early detection
  • Expansion of personalized medicine approaches in treatment protocols

By 2035, the Thyroid Disorder Market is expected to achieve substantial growth and innovation.

Market Segmentation

Thyroid Disorder Market Thyroid Disorder Type Outlook Outlook

  • Hypothyroidism
  • Hyperthyroidism

Thyroid Disorder Market Thyroid Disorder End-User Outlook Outlook

  • Clinics
  • Hospitals
  • Others

Thyroid Disorder Market Thyroid Disorder Treatment Outlook Outlook

  • Medications
  • Surgery
  • Radioactive iodine therapy

Thyroid Disorder Market Thyroid Disorder Route of Administration Outlook Outlook

  • Intravenous
  • Oral
  • Other

Report Scope

MARKET SIZE 20242.511(USD Billion)
MARKET SIZE 20252.617(USD Billion)
MARKET SIZE 20353.948(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)4.2% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesIntegration of telemedicine and digital health solutions in the Thyroid Disorder Market.
Key Market DynamicsRising prevalence of thyroid disorders drives demand for innovative treatment options and enhanced diagnostic technologies.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Thyroid Disorder Market by 2035?

<p>The Thyroid Disorder Market is projected to reach a valuation of 3.948 USD Billion by 2035.</p>

What was the market valuation of the Thyroid Disorder Market in 2024?

<p>In 2024, the Thyroid Disorder Market was valued at 2.511 USD Billion.</p>

What is the expected CAGR for the Thyroid Disorder Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Thyroid Disorder Market during the forecast period 2025 - 2035 is 4.2%.</p>

Which companies are considered key players in the Thyroid Disorder Market?

<p>Key players in the Thyroid Disorder Market include AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, and Merck & Co.</p>

What are the projected revenues for Hypothyroidism and Hyperthyroidism segments by 2035?

<p>By 2035, the projected revenue for Hypothyroidism is 2.368 USD Billion, while Hyperthyroidism is expected to reach 1.58 USD Billion.</p>

What treatment options are available in the Thyroid Disorder Market and their projected revenues?

<p>Projected revenues for treatment options by 2035 include Medications at 1.949 USD Billion, Surgery at 1.174 USD Billion, and Radioactive iodine therapy at 0.825 USD Billion.</p>

How does the route of administration impact the Thyroid Disorder Market?

<p>By 2035, the Oral route of administration is projected to generate 1.951 USD Billion, indicating its significant role in the Thyroid Disorder Market.</p>

What are the expected revenues for different end-users in the Thyroid Disorder Market by 2035?

<p>By 2035, Hospitals are expected to generate 1.563 USD Billion, Clinics 1.174 USD Billion, and Others 1.211 USD Billion.</p>

How does the Thyroid Disorder Market's growth compare to other healthcare sectors?

<p>The Thyroid Disorder Market's growth, with a projected CAGR of 4.2%, suggests a steady expansion compared to other healthcare sectors.</p>

What factors may influence the growth of the Thyroid Disorder Market in the coming years?

<p>Factors such as advancements in treatment options and increasing awareness of thyroid disorders may influence the Thyroid Disorder Market's growth.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Thyroid Disorder Type Outlook (USD Billion)
    2. | | 4.1.1 Hypothyroidism
    3. | | 4.1.2 Hyperthyroidism
    4. | 4.2 Healthcare, BY Thyroid Disorder Treatment Outlook (USD Billion)
    5. | | 4.2.1 Medications
    6. | | 4.2.2 Surgery
    7. | | 4.2.3 Radioactive iodine therapy
    8. | 4.3 Healthcare, BY Thyroid Disorder Route of Administration Outlook (USD Billion)
    9. | | 4.3.1 Intravenous
    10. | | 4.3.2 Oral
    11. | | 4.3.3 Other
    12. | 4.4 Healthcare, BY Thyroid Disorder End-User Outlook (USD Billion)
    13. | | 4.4.1 Clinics
    14. | | 4.4.2 Hospitals
    15. | | 4.4.3 Others
    16. | 4.5 Healthcare, BY Region (USD Billion)
    17. | | 4.5.1 North America
    18. | | | 4.5.1.1 US
    19. | | | 4.5.1.2 Canada
    20. | | 4.5.2 Europe
    21. | | | 4.5.2.1 Germany
    22. | | | 4.5.2.2 UK
    23. | | | 4.5.2.3 France
    24. | | | 4.5.2.4 Russia
    25. | | | 4.5.2.5 Italy
    26. | | | 4.5.2.6 Spain
    27. | | | 4.5.2.7 Rest of Europe
    28. | | 4.5.3 APAC
    29. | | | 4.5.3.1 China
    30. | | | 4.5.3.2 India
    31. | | | 4.5.3.3 Japan
    32. | | | 4.5.3.4 South Korea
    33. | | | 4.5.3.5 Malaysia
    34. | | | 4.5.3.6 Thailand
    35. | | | 4.5.3.7 Indonesia
    36. | | | 4.5.3.8 Rest of APAC
    37. | | 4.5.4 South America
    38. | | | 4.5.4.1 Brazil
    39. | | | 4.5.4.2 Mexico
    40. | | | 4.5.4.3 Argentina
    41. | | | 4.5.4.4 Rest of South America
    42. | | 4.5.5 MEA
    43. | | | 4.5.5.1 GCC Countries
    44. | | | 4.5.5.2 South Africa
    45. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 AbbVie (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Bristol-Myers Squibb (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Eli Lilly and Company (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Merck & Co. (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Novartis (CH)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Pfizer (US)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Sanofi (FR)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Takeda Pharmaceutical Company (JP)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 Amgen (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | 5.3 Appendix
    71. | | 5.3.1 References
    72. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    4. | 6.4 US MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    5. | 6.5 US MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    6. | 6.6 US MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    7. | 6.7 CANADA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    8. | 6.8 CANADA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    9. | 6.9 CANADA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    10. | 6.10 CANADA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    13. | 6.13 GERMANY MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    14. | 6.14 GERMANY MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    15. | 6.15 GERMANY MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    16. | 6.16 UK MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    17. | 6.17 UK MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    18. | 6.18 UK MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    19. | 6.19 UK MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    20. | 6.20 FRANCE MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    21. | 6.21 FRANCE MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    22. | 6.22 FRANCE MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    23. | 6.23 FRANCE MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    24. | 6.24 RUSSIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    25. | 6.25 RUSSIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    26. | 6.26 RUSSIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    27. | 6.27 RUSSIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    28. | 6.28 ITALY MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    29. | 6.29 ITALY MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    30. | 6.30 ITALY MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    31. | 6.31 ITALY MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    32. | 6.32 SPAIN MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    33. | 6.33 SPAIN MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    34. | 6.34 SPAIN MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    35. | 6.35 SPAIN MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    42. | 6.42 CHINA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    43. | 6.43 CHINA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    44. | 6.44 CHINA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    45. | 6.45 INDIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    46. | 6.46 INDIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    47. | 6.47 INDIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    48. | 6.48 INDIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    49. | 6.49 JAPAN MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    50. | 6.50 JAPAN MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    51. | 6.51 JAPAN MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    52. | 6.52 JAPAN MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    61. | 6.61 THAILAND MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    62. | 6.62 THAILAND MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    63. | 6.63 THAILAND MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    64. | 6.64 THAILAND MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    65. | 6.65 INDONESIA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    66. | 6.66 INDONESIA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    67. | 6.67 INDONESIA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    68. | 6.68 INDONESIA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    75. | 6.75 BRAZIL MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    76. | 6.76 BRAZIL MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    77. | 6.77 BRAZIL MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    78. | 6.78 MEXICO MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    79. | 6.79 MEXICO MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    80. | 6.80 MEXICO MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    81. | 6.81 MEXICO MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER TYPE OUTLOOK
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER TREATMENT OUTLOOK
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY THYROID DISORDER END-USER OUTLOOK
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY THYROID DISORDER TYPE OUTLOOK, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY THYROID DISORDER TYPE OUTLOOK, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY THYROID DISORDER TREATMENT OUTLOOK, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY THYROID DISORDER TREATMENT OUTLOOK, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY THYROID DISORDER END-USER OUTLOOK, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY THYROID DISORDER END-USER OUTLOOK, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY THYROID DISORDER TYPE OUTLOOK, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY THYROID DISORDER TREATMENT OUTLOOK, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY THYROID DISORDER ROUTE OF ADMINISTRATION OUTLOOK, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY THYROID DISORDER END-USER OUTLOOK, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Thyroid Disorder Type Outlook (USD Billion, 2025-2035)

  • Hypothyroidism
  • Hyperthyroidism

Healthcare By Thyroid Disorder Treatment Outlook (USD Billion, 2025-2035)

  • Medications
  • Surgery
  • Radioactive iodine therapy

Healthcare By Thyroid Disorder Route of Administration Outlook (USD Billion, 2025-2035)

  • Intravenous
  • Oral
  • Other

Healthcare By Thyroid Disorder End-User Outlook (USD Billion, 2025-2035)

  • Clinics
  • Hospitals
  • Others
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓